| 3rd Mar 2025 3:00 pm |
RNS |
Total Voting Rights |
| 3rd Mar 2025 7:00 am |
RNS |
Imfinzi recommended for EU approval for AEGEAN |
| 28th Feb 2025 1:00 pm |
RNS |
Enhertu recommended in EU in post-ET breast cancer |
| 26th Feb 2025 7:00 am |
RNS |
Camizestrant improved PFS in 1L HR+ breast cancer |
| 19th Feb 2025 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 18th Feb 2025 2:00 pm |
RNS |
Holding(s) in Company |
| 18th Feb 2025 11:00 am |
RNS |
Annual Financial Report |
| 18th Feb 2025 7:00 am |
RNS |
Directorate Change |
| 6th Feb 2025 7:00 am |
RNS |
Final Results |
| 3rd Feb 2025 5:00 pm |
RNS |
Total Voting Rights |
| 3rd Feb 2025 7:00 am |
RNS |
Imfinzi recommended for EU approval for LS-SCLC |
| 28th Jan 2025 7:00 am |
RNS |
Enhertu approved in US for breast cancer post ET |
| 20th Jan 2025 7:00 am |
RNS |
Dato-DXd approved in US for HR+ breast cancer |
| 17th Jan 2025 7:00 am |
RNS |
Calquence combination approved in US for 1L MCL |
| 2nd Jan 2025 3:00 pm |
RNS |
Total Voting Rights |
| 24th Dec 2024 7:00 am |
RNS |
Dato-DXd NSQ NSCLC application withdrawn in EU |
| 23rd Dec 2024 7:00 am |
RNS |
Tagrisso approved in EU based on LAURA trial |
| 16th Dec 2024 7:00 am |
RNS |
Directorate Change |
| 5th Dec 2024 7:00 am |
RNS |
Imfinzi approved in US for limited-stage SCLC |
| 4th Dec 2024 1:45 pm |
RNS |
AstraZeneca appoints Iskra Reic EVP International |
| 2nd Dec 2024 3:05 pm |
RNS |
Block listing Interim Review |
| 2nd Dec 2024 3:00 pm |
RNS |
Total Voting Rights |
| 25th Nov 2024 7:00 am |
RNS |
Truqap improved rPFS in advanced prostate cancer |
| 20th Nov 2024 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 18th Nov 2024 7:00 am |
RNS |
Tagrisso recommended for EU approval - LAURA |
| 15th Nov 2024 2:00 pm |
RNS |
Director/PDMR Shareholding |
| 15th Nov 2024 10:00 am |
RNS |
Director/PDMR Shareholding |
| 13th Nov 2024 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 12th Nov 2024 7:10 am |
RNS |
AstraZeneca invests $3.5 billion in US |
| 12th Nov 2024 7:05 am |
RNS |
KOMET Phase III trial met primary endpoint |
| 12th Nov 2024 7:00 am |
RNS |
9M and Q3 2024 Results |
| 12th Nov 2024 7:00 am |
RNS |
Dato-DXd new BLA submitted, NSQ BLA withdrawn |
| 8th Nov 2024 7:00 am |
RNS |
Tezspire nasal polyps trial met primary endpoints |
| 5th Nov 2024 4:49 pm |
RNS |
AZN share price movement |
| 1st Nov 2024 3:00 pm |
RNS |
Total Voting Rights |
| 30th Oct 2024 1:00 pm |
RNS |
AZN China President under investigation |
| 21st Oct 2024 7:00 am |
RNS |
Wainzua recommended for approval in the EU |
| 7th Oct 2024 9:30 am |
RNS |
AstraZeneca licenses lipid lowering Lp(a) asset |
| 1st Oct 2024 3:00 pm |
RNS |
Total Voting Rights |
| 26th Sep 2024 7:00 am |
RNS |
Tagrisso US approval in unresectable lung cancer |
